key: cord-0278651-cjnjsqvm
authors: Bekliz, M.; Adea, K.; Vetter, P.; Eberhardt, C. S.; Hosszu-Fellous, K.; Vu, D.-L.; Puhach, O.; Essaidi-Laziosi, M.; Waldvogel-Abramowski, S.; Stephan, C.; L'Huillier, A.; Siegrist, C.-A.; Didierlaurent, A. M.; Kaiser, L. M.; Meyer, B.; Eckerle, I.
title: Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants
date: 2021-12-31
journal: nan
DOI: 10.1101/2021.12.28.21268491
sha: d3c13a6683d0eb5916f071a4b4e94cd19df42522
doc_id: 278651
cord_uid: cjnjsqvm

Emerging SARS-CoV-2 variants of concern/interest (VOC/VOI) raise questions about effectiveness of neutralizing antibodies derived from infection or vaccination. Here, we have assessed a total of 104 blood specimens, consisting of convalescent samples after infection with early-pandemic SARS-CoV-2 (pre-VOC) or with Alpha, Beta, Gamma or Delta, post-vaccination samples after double-dose mRNA-vaccination as well as samples after vaccine break-through infections with Delta or Omicron. Neutralization against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta, Omicron) was assessed by plaque-reduction neutralization assay. We found highest neutralization titers against the homologous (previously infecting) variant, with lower neutralization efficiency against heterologous variants. Loss of neutralization against heterologous variants showed considerably variability between convalescent groups suggesting that a variant-specific infection background influences immune escape characteristics. Convalescent samples from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta-infected individuals all showed a significant loss of neutralization for Omicron but to a varying degree (23.0-fold in Beta-convalescent up to 56.1-fold in Alpha-convalescent samples), suggesting that infection-derived immunity, independent of the infecting variant is most likely only poorly protective against Omicron. Of note, former variant of concern Zeta showed also a pronounced escape form neutralization of up to 28.2-fold in Alpha convalescent samples. Two-dose vaccinated individuals showed robust neutralization against B.1 and only slightly lower neutralization titers for Alpha, Beta, Gamma, Delta and Zeta, with fold-change reduction for heterologous virus between 2.8 (for Alpha) to 6.9 (for Beta). In contrast to convalescent specimens, escape from neutralization for Zeta was largely restored in vaccinated individuals, while Omicron showed a strongly reduced neutralization of 85.7-fold compared to pre-VOC SARS-CoV-2. Robust neutralization titers were observed in double-vaccinated individuals with subsequent Delta break-through infections, that also neutralized Omicron with a loss of only 12.5-fold. Individuals with an Omicron breakthrough infection showed high neutralization titers for both Delta and Omicron, with only a 1.5-fold loss for Delta neutralization. This suggests that infection with antigenically different variants can boost immunity against variants that are antigenically similar to the vaccine strain. We conclude that for the assessment of escape from neutralization by new VOCs such as Omicron, the complexity of background immunity due to individual and regional differences needs to be taken into account. Geographic variation in the proportion of individual with infection- or vaccination-derived immunity or a combination of both could have substantial influence on the course of the pandemic. Combined infection/vaccination immunity after break-through infections could ultimately lead to broad immunity also against non-homologous variants.

In late 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged 86 in Wuhan (China) causing a pandemic that led to an unprecedented international health crisis 87 of yet unknown outcome [1, 2] . Shortly after its emergence, SARS-CoV-2 acquired the D614G 88 mutation in the spike protein in February 2020, which quickly replaced all other circulating 89 variants and spread worldwide. The evolutionary advantage of D614G is associated with 90 enhanced binding to the human receptor and increased replication and thus presumably better 91 transmissibility [3] . After largely uncontrolled transmission on a global scale during 2020, the 92 emergence of the first variants of concern (VOCs) was observed [4] . The VOCs consist of the In addition to VOCs, other variants were identified that were of less concern and therefore 102 classified as variants of interest (VOI) due to aspects in their epidemiology or genetic 103 signatures potentially leading to an altered phenotype, among them the (former) VOI Zeta that 104 arose in parallel with the Gamma variant in South America at a time when a local surge in 105 cases was observed but has disappeared in the meanwhile [6] [7] [8] [9] [10] . 106 Currently, few treatments are widely available for SARS-CoV-2 and mostly dedicated to risk 107 groups, therefore prevention and protection through vaccine-mediated immunity is still the 108 proposed method for ending the pandemic [11] . Depending on countries, medium to high levels is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 potent neutralizing antibodies [12] , as does the mRNA-based vaccine Moderna mRNA-1273, 119 encoding a stabilized prefusion SARS-CoV-2 spike protein [13] . However, emerging SARS- studies indicated that mutations that have been accumulating in the spike protein, especially in 126 the RBD, are associated with increased affinity to the human ACE2 receptor [14] , as well as 127 with resistance to neutralization from antibodies of previously infected or vaccinated patients 128 [15] . Mutations in the RBD pose the greatest risk for making SARS-CoV-2 more infectious 129 and able to escape antibody neutralization [14] . Virus neutralizing antibody have been shown 130 to be a correlate of protection from SARS-CoV-2 but more insights on neutralizing responses 131 against emerging virus variants are needed [16] [17] [18] [19] . 132 In this study, we investigated the neutralizing potency of a panel of authentic sera or plasma is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint of SARS-CoV-2 in our diagnostic unit, and sera/plasma were collected 3-137 days after 174 diagnosis or symptom onset (days post diagnosis, DPP). All vaccinated individuals were in 175 addition tested for the presence of nucleocapsid antibodies (Elecsys® Anti-SARS-CoV-2 anti-176 N) to screen for unrecognized infection prior to vaccination. There are no differences to be 177 expected in the PRNT regarding the use of plasma or serum, therefore both sample types are 178 used in parallel and termed "convalescent samples" throughout the manuscript.

Viruses and cells. 180 Vero-E6 and Vero E6-TMPRSS cells were cultured in complete DMEM GlutaMax I medium 181 supplemented with 10% fetal bovine serum, 1x Non-essential Amino Acids, and 1% antibiotics 182 . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint were titrated on Vero-E6 cells and full genome sequenced. Sequences of initial patient 196 specimens and virus isolates obtained were compared for acquired mutations (Table S1) . 197 Experiments with live infectious SARS-CoV-2 followed the approved standard operating 198 procedures of our biosafety level 3 facility (BSL-3).

Following the PRNT procedure, Vero-E6 cells were seeded at a density of 4x10 5 cells/mL in Delta, Zeta and Omicron) and incubated at 37°C for 1h. All samples were run in duplicate and 210 for each neutralization experiment an infection control (no serum/plasma) and a reference 211 serum were used to ensure reproducibility between different experiments. Vero-E6 cells were 212 washed 1x with PBS and inoculated with the virus serum/plasma mixture for 1h. Afterwards, 213 the inoculum was removed and 500uL of the overlay medium also used for the plaque assays 214 was added. After incubation for 3 days at 37°C, 5% CO2, the overlay medium was removed, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint cells were fixed in 6% formaldehyde solution for at least 1h, plates were washed 1x with PBS 216 and stained with crystal violet. Plaques were counted in wells inoculated with virus-217 serum/plasma mixtures and compared to plaque counts in infection control wells. The 90% 218 reduction endpoint titers (PRNT90) were calculated by fitting a 4-parameter logistics curve with 219 variable slope to the plaque counts of each serum/plasma using GraphPad Prism version 9.2.0.

For samples that did not reach 90% reduction at a 1:10 dilution, we extrapolated the titer until 221 a dilution of 1, i.e. undiluted sample. If the extrapolation reached a titer below 1, the sample 222 was given a value of 0.5 and considered negative. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint 3.6) for Zeta and 0.8 (95%CI:0.4-1.7) for Omicron. Compared to the homologous Alpha 246 variant, this results in a reduction of 1.6 (B.1), 6.2 (Beta), 12.0 (Gamma), 7.7 (Delta), 28.2 247 (Zeta) and 56.1 (Omicron). Complete loss of neutralization was observed for 3/12 (25%) 248 samples for Gamma, 1/12 (8%) for Delta, 5/12 (42%) for Zeta and 10/12 (83%) for Omicron 249 (Fig. 1B) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021.

We investigated a total of 30 patient specimens from either double-vaccinated individuals 279 (n=16) or with combined vaccination-infection-derived immunity, either through prior 280 infection followed by vaccination, or vaccination followed by a vaccine-break through 281 infection with Delta or Omicron (n=14).

In contrast to all infection-derived convalescent samples, geometric mean PRNT90 titers were In addition, we have investigated vaccinated individuals with a break-through infection with 302 Delta (n=4) and Omicron (n=4) for neutralization against both viruses which are currently the 303 only VOCs co-circulating. For the first group, high geometric mean PRNT90 titers of 1636 304 (95%CI: 128.2-20885) were observed for the Delta while 130.9 (95%CI:24.9-688.9) was 305 observed for Omicron. This results in a 12.5-fold reduction versus the homologous Delta, but 306 no complete loss of neutralization was observed (Fig. 2C) . For Omicron break-through 307 infection following vaccination, geometric mean PRNT90 titers were 913.5 (95%CI:341.8-308 2442) was observed for Omicron, and 627.9 (95%CI:269.5-1463) was observed for Delta, 309 which equals a 1.5-fold loss of neutralization to heterologous Delta (Fig. 2 D) . Highest titers 310 were seen against the infecting variant Omicron compared to Delta, although the prior vaccine-311 derived immunity by an early pandemic spike is antigenically closer to Delta than to Omicron. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint In addition to cumulated data ( Fig. 1 and 2) , neutralization profiles were also displayed on an 316 individual basis (Figure S1-S9) . Here, inter-individual differences both in quantity of antibody 317 response as well as patterns of neutralization loss towards heterologous variants were observed, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint We observed a reduction of neutralization capacity by first-wave SARS-CoV-2 convalescent 347 and post-vaccine samples towards Alpha, Beta, Gamma and Delta to a comparable extent than 348 what was described by others [27, [29] [30] [31] [32] . While for the Alpha variant, only slightly reduced 349 neutralization was described for both convalescent and vaccinee sera, a more pronounced is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint between fold-change reduction of Zeta and Omicron were much bigger, with Omicron showing 376 a 3-5-fold higher escape of neutralization compared to Zeta. At least for Gamma, robust 377 neutralization for Zeta could be explained by a common origin as both are descendants from is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint on receptor binding and neutralization [46] [47] [48] [49] . While the mutation can explain, at least partly, 408 the strong escape from neutralization in Omicron, it has no or only very low influence on 409 ACE2-binding and is therefore most likely not associated with higher transmissibility, although 410 the mechanism of transmissibility in Omicron is not well understood [50] . 411 We have shown that Omicron exhibits a strong escape from neutralization in both convalescent 412 and vaccine sera, although differences in fold change reduction exist depending on prior 413 infection background. However, it has been shown that a third dose of a mRNA vaccine is able 414 to restore neutralizing capacity [51] [52] [53] [54] . Similarly, individuals with mixed immunity, i.e. Population immunity and evolutionary pressure might differ on a regional scale depending on is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint harbor immune escape properties such as Omicron. Although the origin of Omicron is not well 440 understood, it was speculated that a high background of Beta-variant immunity has favored the 441 development of Omicrons immune escaping properties [58] . In contrast to earlier variants, 442 Omicron is showing a rapid increase in cases with a short doubling time, in addition to its 443 immune-escaping properties [59] . This, together with reduced neutralization is also suggestive 444 of decreased vaccine effectiveness, will further complicate the management of the pandemic.

Limitations of our study are the relatively low number of specimens that were available for 446 convalescent specimens of patients previously infected with variants. Furthermore, we cannot is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101/2021.12.28.21268491 doi: medRxiv preprint figure. Colored numbers below each bar represents number of specimens with complete loss 510 of neutralization (PRNT90 titer < 1). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 31, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Figure S1 . Convalescent pre-VOC (n=34) Figure S1 . Convalescent pre-VOC (n=34) Figure S1 . Convalescent Gamma (n=10) Figure S4 . 

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat 529 origin

SARS-CoV-2 spike D614G change enhances replication and transmission. 531 Nature

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern 535

Detection of a SARS-CoV-2 variant of concern in South Africa

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in 539 England

Increased transmissibility and global spread of SARS-CoV-2 variants of 541 concern as at

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. 543 Science

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de 545 Janeiro

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. 548

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Vaccine-escape and fast-growing mutations in the United Kingdom

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in 557 Humans during a Fishery Vessel Outbreak with a High Attack Rate

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding 623 domain that affect recognition by polyclonal human plasma antibodies

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 626 convalescent plasma. bioRxiv

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that 628 attenuate monoclonal and serum antibody neutralization. bioRxiv

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals 632 Constraints on Folding and ACE2 Binding

mRNA-based COVID-19 vaccine boosters induce neutralizing 634 immunity against SARS-CoV-2 Omicron variant. medRxiv

Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape 636 from Neutralizing Antibodies. medRxiv

Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection

Enhanced neutralization against SARS-CoV-2 by vaccine booster exhibits 640 reduction of Omicron variant

Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in 642 vaccinated and previously infected individuals, the Netherlands

Original Antigenic Sin: the Downside of Immunological 645 Memory and Implications for COVID-19. mSphere

Neutralizing antibody responses over time in demographically and clinically 647 diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A 648 cohort study

Receptor binding and escape from Beta antibody responses drive Omicron-650 B.1.1.529 evolution. bioRxiv

SARS-CoV-2 transmission dynamics in South Africa and 652 epidemiological characteristics of the Omicron variant

Evolution of antibody immunity to SARS-CoV-2

Vaud Host Human Human Human Human Human Human Human

Bekliz M et al.